Reviewing CohBar Inc. (CWBR)’s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s results

CohBar Inc. (NASDAQ:CWBR) and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CohBar Inc. N/A 0.00 14.35M -0.35 0.00
Dicerna Pharmaceuticals Inc. 6.91M 98.84 93.05M -2.23 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for CohBar Inc. and Dicerna Pharmaceuticals Inc.

Profitability

Table 2 provides us CohBar Inc. and Dicerna Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
CohBar Inc. 0.00% -96.8% -80.6%
Dicerna Pharmaceuticals Inc. -1,346.60% -90.8% -74.4%

Volatility & Risk

CohBar Inc.’s volatility measures that it’s 6.00% more volatile than Standard & Poor’s 500 due to its 1.06 beta. Competitively, Dicerna Pharmaceuticals Inc. is 138.00% more volatile than Standard & Poor’s 500, because of the 2.38 beta.

Liquidity

The Current Ratio of CohBar Inc. is 33.2 while its Quick Ratio stands at 33.2. The Current Ratio of rival Dicerna Pharmaceuticals Inc. is 6.3 and its Quick Ratio is has 6.3. CohBar Inc. is better equipped to clear short and long-term obligations than Dicerna Pharmaceuticals Inc.

Analyst Ratings

In next table is shown CohBar Inc. and Dicerna Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CohBar Inc. 0 0 0 0.00
Dicerna Pharmaceuticals Inc. 0 0 4 3.00

Competitively Dicerna Pharmaceuticals Inc. has an average target price of $25, with potential upside of 129.57%.

Institutional and Insider Ownership

CohBar Inc. and Dicerna Pharmaceuticals Inc. has shares held by institutional investors as follows: 9.6% and 88.6%. Insiders held roughly 4.5% of CohBar Inc.’s shares. Competitively, 0.1% are Dicerna Pharmaceuticals Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CohBar Inc. -12.47% -9.37% -24.31% -61.17% -22.17% -27.97%
Dicerna Pharmaceuticals Inc. -14.76% -14.58% -20.51% 1.03% 66.36% 40.75%

For the past year CohBar Inc. had bearish trend while Dicerna Pharmaceuticals Inc. had bullish trend.

Summary

Dicerna Pharmaceuticals Inc. beats on 6 of the 10 factors CohBar Inc.

CohBar, Inc., a biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. Its lead MBT drug candidates include CB4209 and CB4211, which are in IND-enabling studies for the treatment of fatty liver disease, non-alcoholic steatohepatitis, obesity, and type 2 diabetes mellitus. The company is also developing Humanin, a mitochondrial-derived peptide to treat AlzheimerÂ’s disease, atherosclerosis, myocardial and cerebral ischemia, and type 2 diabetes mellitus; SHLP-6 for the treatment of cancer; and SHLP-2 to treat AlzheimerÂ’s disease and type 2 diabetes mellitus. CohBar, Inc. was founded in 2007 and is headquartered in Menlo Park, California.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.